Genedata Launches AI Platform for Drug Manufacturing and Development
Genedata, a company under Danaher Corporation, announced in a press release the launch of Genedata Vico, an AI based platform designed to accelerate Chemistry, Manufacturing, and Controls (CMC) processes in drug development and production. The solution was co-developed with several top ten pharmaceutical companies and recognized by Bio-IT World with the 2026 Innovative Practices Award for Real-World AI.
Genedata Vico integrates experimental data and metadata from multiple sources across biologics and small molecule development to create analysis ready datasets that maintain context and lineage. It supports CMC data scientists in applying proprietary or commercial AI models with full tracking and lifecycle management, allowing teams to visualize and analyze data supported by domain specific AI agents.
The platform enables AI assisted process analytical technology for monitoring drug quality during production and supports data based design of experiments and quality by design methods. It is built on Anthropic's Claude model family and includes a GxP compliant Model Context Protocol server for integration into enterprise frameworks.
According to benchmarking by its pharmaceutical partners, use of Genedata Vico can recover up to 80 percent of losses typically incurred from failed batches and avoid up to 15 months of clinical trial supply delays each year. The company plans to present the platform and its performance results at the Bio-IT World Conference and Expo.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly, Industrial AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 20 Danaher and Microsoft build an agentic platform for lab instruments Nov 19 Knit Health raises $35 million to roll out its healthcare world model Nov 19 Banner Health invests in Layer Health and moves its clinical registries onto its AI platform Nov 19 Half of Koreans who changed medication on AI advice had side effects, survey finds Nov 19 Isomorphic Labs and MSD team up to design cancer drugs with AILife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
Danaher and Microsoft build an agentic platform for lab instruments
Atlas Bio raises $12.5 million for virtual drug trials
Cognizant Launches AI Nexus to Track AI Costs and Quality
PharmaForceIQ Launches Share of Answer for Pharma AI Visibility
Databricks Updates Genie for Multistep Business Tasks
Daily AI Brief: the AI news that matters, in your inbox.